Post Photo


Bold Therapeutics and Hana Pharm Extend Option Agreement for BOLD-100, a First-in-Class Anti-Resistance Therapeutic

Bold Therapeutics announces an extension of the option agreement with Hana Pharm for development and commercialization rights to BOLD-100 in South Korea.

Post Photo


BOLD-100 Exhibits Potent Anti-Tumor Activity in Validated I/O In Vivo Models

Bold Therapeutics has demonstrated potent anti-tumor activity in combination with a PD-1 checkpoint inhibitor in an in vivo model of colorectal cancer.

Post Photo


Bold Therapeutics Receives FDA Clearance to Add U.S. Sites for Phase 1b / 2a Trial of BOLD-100 in the Treatment of Advanced GI Cancers

Bold Therapeutics announces the addition of U.S. Sites for its phase 1b / 2a trial of BOLD-100 in the treatment of advanced GI cancers.

Post Photo


Bold Therapeutics Receives Additional Funding to Support Development of BOLD-100 as a Novel Antiviral

Bold Therapeutics announces it is receiving additional funding of up to CAD$965,000 from NRC IRAP to support the development of BOLD-100 as a novel antiviral.

Post Photo


BOLD-100 Effective In Vitro Against COVID-19 Variants

Bold Therapeutics announces that new research completed by collaborators shows BOLD-100 consistently reduced viral concentrations in COVID-19 variants.

Post Photo


BOLD-100 MoA Research to Be Presented at the AACR Annual Meeting

Dr. Van Schaeybroeck will present research supporting BOLD-100 as a potential anti-resistance therapy for BRAF-mutant colorectal cancer at AACR annual meeting.

Post Photo


Bold Therapeutics Secures Funding to Prepare BOLD-100 for COVID-19 Clinical Trials

Bold Therapeutics announces that it is one of four companies selected to receive funding from the National Research Council of Canada for its COVID-19 research.

Post Photo


Bold Therapeutics COVID-19 Program Chosen by National Research Council of Canada for Development Support

Bold Therapeutics BOLD-100 program was one of only four COVID-19 therapeutics programs selected by the National Research Council for development support.

Post Photo


Bold Therapeutics Successfully Initiates Clinical Trial of First-in-Class Anti-Cancer Agent BOLD-100

Bold Therapeutics announced that the first patient for the company’s Phase 1b clinical trial has been enrolled at the Cross Cancer Institute.

Post Photo


BOLD-100 Shows Inhibition of DNA Repair Pathways in Breast Cancer

Georgetown University has recently published a new manuscript showing that Bold Therapeutics’ BOLD-100 has anti-cancer potential in breast cancer.

Post Photo


BOLD-100 Significantly Outperforms Remdesivir Head-to-Head in SARS-CoV-2 (COVID-19) Model

Bold Therapeutics recently generated additional data supporting rapid clinical development of BOLD-100 as a novel antiviral.

Post Photo


BOLD-100 Demonstrates Nanomolar Range Inhibition of Live COVID-19 In Vitro

Bold Therapeutics has in vitro data showing that its lead clinical-stage therapeutic, BOLD-100, successfully inhibits live SARS-CoV-2 (COVID-19).

Post Photo


Bold Therapeutics Expands COVID-19 Consortium

Bold Therapeutics is excited to expand its COVID-19 consortium to include four additional collaborators from prominent institutions in Canada and the U.K.

Post Photo


Bold Therapeutics and Hana Pharm Execute Option Agreement for Exclusive Development and Commercialization Rights to BOLD-100 in South Korea

Bold Therapeutics announced it has executed an option agreement with Hana Pharm Co. for BOLD-100 in South Korea.

Post Photo


Bold Therapeutics Seeks Collaborators for Rapid Development of BOLD-100; Lead Drug Candidate Has Potential Utility in the Treatment of COVID-19

Bold Therapeutics announced that recent developments have suggested the potential utility of its lead drug BOLD-100 as a novel antiviral agent.

Post Photo


Bold Therapeutics to Initiate Phase 1b Trial of BOLD-100 in GI Cancers

Bold Therapeutics announced that it has received clearance from Health Canada to initiate a Phase 1b trial.